French pharma firm ordered to pay millions over deadly diabetes drug
The drug, which may have caused up to 1,800 deaths, was later banned in France where millions of people took it.
It is also banned in the United States, Spain and Italy.
In the latest court ruling in more than a decade of legal proceedings, the Paris appeals court upheld verdicts of "aggravated fraud" and "involuntary manslaughter and injuries".
It ordered Servier to pay a 9-million-euro ($9.8- million) fine and pay back more than 415 million euros ($455 million) to the national social security agency and health insurance companies, much higher damages than in an initial ruling in 2021.
The EMA bans Pneumorel, a drug from the French laboratory Servier, owing to two deaths in 50 years, but fails to react to the 12 000 deaths reported following COVID vaccination
Fenspiride (Pneumorel) had been used to treat symptoms of respiratory diseases (notably as a cough medicine). Why does the Commission consider that the risks outweigh the benefits of Pneumorel – even though it is used to treat symptoms of a mild disease and the only serious effects linked to its safety have been the five cases of heart problems reported in 50 years globally – and yet for the COVID vaccines, the 12 000 deaths reported in the space of one or two years[6] and the confirmed risk of fatal myocardial do not influence the benefit-risk ratio for certain populations (healthy young people / soldiers), even after the end of the pandemic was announced by the WHO on 5 May 2023?
BEWARE Servier's Cancer Drug:
More lab space: French pharma Servier is growing its cancer business in Seaport
The French drug company Servier is doubling down on its presence in Boston with a new research lab and an expanded US headquarters in the Seaport District. The expansion is part of the company’s plans to become an oncology powerhouse in Boston and grow its business in the United States.
Until four years ago, the company barely had a foothold in the city. That changed with the acquisition of cancer drug franchises from two companies with Massachusetts ties: a $2.4 billion deal for Shire Pharmaceuticals’ cancer business in 2018 and a $1.8 billion acquisition of Agios Pharmaceuticals’ cancer business in 2021. Now, more deals could be on the way.
PARIS, Feb. 2, 2023 /PRNewswire/ -- Servier, an independent global pharmaceutical group, has announced its financial results for the 2021/22 financial year and highlighted the major steps of its ongoing transformation. Sales revenue for brand-name medicines reached €3.694 billion, up 12.5% (+8.9% at CERi), and €1.182 billion for generics, up 2.0% (stable at CERi) Servier full year 2021/22 results confirm the transformation trajectory of the Group | BioSpace
And it's quite convenient that the Covid jabs are linked to an uptick in cancers. Oh, the evil cycle. Pharmacy is against God's Law.